BASF   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mannheim Germany (1865)
Status: Acquired by IG Farben (1925)

Organization Overview

First Clinical Trial
1997
NCT00198718
First Marketed Drug
1981
ibuprofen (motrin)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BASF | BASF AS | BASF (v1) | BASF (v2) | Nunhems

Active Ingredients

Marketed Drugs (1)

ibuprofen (motrin) (1981)

Drugs in Phase 4 Trials (2)

Key: BASF (0) Acquired (2)

etanercept (enbrel) (1 trial)

icosapent ethyl (vascepa) (16 trials)

Drugs in Phase 3 Trials (3)

Key: BASF (0) Acquired (3)

corn (2 trials)

omega-3 fatty acids (Omacor) (3 trials)

vitamin e (1 trial)

Drugs in Phase 2 Trials (4)

Key: BASF (1) Acquired (3)

icosabutate (5 trials)

olive (6 trials)

prevastein hc (1 trial)

vitamin a (1 trial)

Drugs in Phase 1 Trials (1)

Key: BASF (0) Acquired (1)

ethinyl estradiol (Estinyl) (1 trial)

Drugs in Other Trials (11)

Key: BASF (6) Acquired (5)

carotenoid (1 trial)

conjugated linoleic acid (3 trials)

cow milk (1 trial)

docosahexaenoic acid (3 trials)

eicosapentanoic acid (3 trials)

fatty acid (1 trial)

fish oil (Omegavan) (1 trial)

gamma-aminobutyric acid (1 trial)

safflower oil (1 trial)

vitamin d3 (1 trial)

xanthophyll (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Central Nervous System Diseases (Phase 2)

Cognition Disorders (Phase 2)

Cognitive Dysfunction (Phase 2)

Dementia (Phase 2)

Disease (Phase 2)

Inflammation (Phase 2)

Mental Disorders (Phase 2)

Nervous System Diseases (Phase 2)

Neurocognitive Disorders (Phase 2)

Night Blindness (Phase 2)

Pathologic Processes (Phase 2)

Vitamin A Deficiency (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 39
  • # of Trial APIs: 21